BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 19080757)

  • 1. Oculopharyngeal muscular dystrophy: a polyalanine myopathy.
    Brais B
    Curr Neurol Neurosci Rep; 2009 Jan; 9(1):76-82. PubMed ID: 19080757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nuclear speckles are involved in nuclear aggregation of PABPN1 and in the pathophysiology of oculopharyngeal muscular dystrophy.
    Bengoechea R; Tapia O; Casafont I; Berciano J; Lafarga M; Berciano MT
    Neurobiol Dis; 2012 Apr; 46(1):118-29. PubMed ID: 22249111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PABPN1 overexpression leads to upregulation of genes encoding nuclear proteins that are sequestered in oculopharyngeal muscular dystrophy nuclear inclusions.
    Corbeil-Girard LP; Klein AF; Sasseville AM; Lavoie H; Dicaire MJ; Saint-Denis A; Pagé M; Duranceau A; Codère F; Bouchard JP; Karpati G; Rouleau GA; Massie B; Langelier Y; Brais B
    Neurobiol Dis; 2005 Apr; 18(3):551-67. PubMed ID: 15755682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oculopharyngeal muscular dystrophy: a late-onset polyalanine disease.
    Brais B
    Cytogenet Genome Res; 2003; 100(1-4):252-60. PubMed ID: 14526187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The dynamism of PABPN1 nuclear inclusions during the cell cycle.
    Marie-Josée Sasseville A; Caron AW; Bourget L; Klein AF; Dicaire MJ; Rouleau GA; Massie B; Langelier Y; Brais B
    Neurobiol Dis; 2006 Sep; 23(3):621-9. PubMed ID: 16860991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oculopharyngeal muscular dystrophy: recent advances in the understanding of the molecular pathogenic mechanisms and treatment strategies.
    Abu-Baker A; Rouleau GA
    Biochim Biophys Acta; 2007 Feb; 1772(2):173-85. PubMed ID: 17110089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of PABPN1 nuclear inclusions on a large cohort of patients and in a human xenograft model of oculopharyngeal muscular dystrophy.
    Roth F; Dhiab J; Boulinguiez A; Mouigni HR; Lassche S; Negroni E; Muraine L; Marhic A; Oliver A; Lainé J; Rouche A; O'Ferrall EK; van Engelen B; Ottenheijm C; Greif H; Blumen S; Lacau St Guily J; Perie S; Butler-Browne G; Mouly V; Trollet C
    Acta Neuropathol; 2022 Dec; 144(6):1157-1170. PubMed ID: 36197469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Drosophila model of oculopharyngeal muscular dystrophy reveals intrinsic toxicity of PABPN1.
    Chartier A; Benoit B; Simonelig M
    EMBO J; 2006 May; 25(10):2253-62. PubMed ID: 16642034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel mouse models of oculopharyngeal muscular dystrophy (OPMD) reveal early onset mitochondrial defects and suggest loss of PABPN1 may contribute to pathology.
    Vest KE; Phillips BL; Banerjee A; Apponi LH; Dammer EB; Xu W; Zheng D; Yu J; Tian B; Pavlath GK; Corbett AH
    Hum Mol Genet; 2017 Sep; 26(17):3235-3252. PubMed ID: 28575395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular and phenotypic characterization of a mouse model of oculopharyngeal muscular dystrophy reveals severe muscular atrophy restricted to fast glycolytic fibres.
    Trollet C; Anvar SY; Venema A; Hargreaves IP; Foster K; Vignaud A; Ferry A; Negroni E; Hourde C; Baraibar MA; 't Hoen PA; Davies JE; Rubinsztein DC; Heales SJ; Mouly V; van der Maarel SM; Butler-Browne G; Raz V; Dickson G
    Hum Mol Genet; 2010 Jun; 19(11):2191-207. PubMed ID: 20207626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progress on gene therapy, cell therapy, and pharmacological strategies toward the treatment of oculopharyngeal muscular dystrophy.
    Harish P; Malerba A; Dickson G; Bachtarzi H
    Hum Gene Ther; 2015 May; 26(5):286-92. PubMed ID: 25860803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Case of Oculopharyngeal Muscular Dystrophy Caused by a Novel PABPN1 c.34G > T (p.Gly12Trp) Point Mutation without Polyalanine Expansion.
    Takahashi Y; Morimoto N; Nada T; Morimoto M; Eura N; Minami N; Nishino I
    J Neuromuscul Dis; 2023; 10(3):459-463. PubMed ID: 36847015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional impact of an oculopharyngeal muscular dystrophy mutation in PABPN1.
    García-Castañeda M; Vega AV; Rodríguez R; Montiel-Jaen MG; Cisneros B; Zarain-Herzberg A; Avila G
    J Physiol; 2017 Jul; 595(13):4167-4187. PubMed ID: 28303574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intranuclear Aggregates Precede Clinical Onset in Oculopharyngeal Muscular Dystrophy.
    van der Sluijs BM; Raz V; Lammens M; van den Heuvel LP; Voermans NC; van Engelen BG
    J Neuromuscul Dis; 2016 Mar; 3(1):101-109. PubMed ID: 27854203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mitochondrial localization of PABPN1 in oculopharyngeal muscular dystrophy.
    Doki T; Yamashita S; Wei FY; Hara K; Yamamoto T; Zhang Z; Zhang X; Tawara N; Hino H; Uyama E; Kurashige T; Maruyama H; Tomizawa K; Ando Y
    Lab Invest; 2019 Nov; 99(11):1728-1740. PubMed ID: 30894671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of the ubiquitin-proteasome system contributes to oculopharyngeal muscular dystrophy through muscle atrophy.
    Ribot C; Soler C; Chartier A; Al Hayek S; Naït-Saïdi R; Barbezier N; Coux O; Simonelig M
    PLoS Genet; 2022 Jan; 18(1):e1010015. PubMed ID: 35025870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of
    Cruz-Aguilar M; Guerrero-de Ferran C; Tovilla-Canales JL; Nava-Castañeda A; Zenteno JC
    J Investig Med; 2017 Mar; 65(3):705-708. PubMed ID: 27980005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progress in understanding the pathogenesis of oculopharyngeal muscular dystrophy.
    Fan X; Rouleau GA
    Can J Neurol Sci; 2003 Feb; 30(1):8-14. PubMed ID: 12619777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mitochondrial dysfunction reveals the role of mRNA poly(A) tail regulation in oculopharyngeal muscular dystrophy pathogenesis.
    Chartier A; Klein P; Pierson S; Barbezier N; Gidaro T; Casas F; Carberry S; Dowling P; Maynadier L; Bellec M; Oloko M; Jardel C; Moritz B; Dickson G; Mouly V; Ohlendieck K; Butler-Browne G; Trollet C; Simonelig M
    PLoS Genet; 2015 Mar; 11(3):e1005092. PubMed ID: 25816335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation between PABPN1 genotype and disease severity in oculopharyngeal muscular dystrophy.
    Richard P; Trollet C; Stojkovic T; de Becdelievre A; Perie S; Pouget J; Eymard B;
    Neurology; 2017 Jan; 88(4):359-365. PubMed ID: 28011929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.